Chemical structures of dopamine, istradefylline, and MB-204 with dopamine D2 and adenosine A2A receptors shown below.

FRAXA-DVI Study Finds Promising Results for Marvel Biosciences’ A2A Receptor Drug in Fragile X Model

August 6, 2026

FRAXA-DVI study finds Marvel Biosciences’ MB-204, an A2A receptor blocker, improved behavior and cognition in a Fragile X mouse model.

Read More »

Marvel Biosciences Partners with FRAXA to Test MB204 for Fragile X Syndrome

August 20, 2024

Marvel Biosciences and FRAXA Research Foundation are collaborating to test MB204, a promising new treatment for Fragile X which targets adenosine receptors.

Read More »

Characterization of Microglia Transcriptional Profile in Fmr1 Knockout Mice Model

July 1, 2021

Microglia are excessively activated in Fragile X models. The team will investigate the mechanisms and attempt to correct this using drugs.

Read More »

Parkinson’s Therapy May Hold Promise for Fragile X

February 24, 2021

A study funded by FRAXA in Italy has encouraging results for people with Fragile X: drugs that block adenosine receptors (A2A) reversed signs of Fragile X in a mouse model.

Read More »
Antonella Borreca, PhD, and Alberto Martire, PhD

Coffee, Tea, and Chocolate: Adenosine Receptors in Fragile X

December 11, 2018

Could “caffeine-like” drugs help Fragile X? FRAXA funded research to test adenosine blockers, which may boost thinking and improve symptoms in Fragile X mice.

Read More »

Categories

FRAXA Funded Research

Current Research Grants (41)